Leading health innovation around the world

At LivaNova, we are committed to enhancing shareholder value driven by our mission and values that guide our strategy as a company. We are a strong, market-leading medical technology and innovation company, offering a diverse product portfolio and global reach. Through our work, we are improving the quality of life for every patient, every day.

LivaNova is listed on the NASDAQ stock exchange under the ticker symbol "LIVN."

LivaNova has approximately 3,000 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries.

LivaNova Therapeutic Areas

We have a strong legacy as leaders in advanced circulatory support, cardiopulmonary and neuromodulation, providing products and therapies in distinct therapeutic areas to treat the head and heart. These include:

Advanced Circulatory Support
We’ve created a cardiopulmonary support system that is designed to be powerful, yet simple to use, in emergency situations. The platform centers around the LifeSPARC pump and controller, along with ready-to-deploy kits for different interventions. Discover more

Cardiopulmonary
As the world’s leading cardiopulmonary bypass company, we make the S5® Heart-Lung Machine, oxygenators, and other products and systems for perfusion. Discover more

Difficult-to-Treat Depression
Our VNS Therapy® System, SYMMETRY, treats patients with difficult-to-treat depression (DTD) and may provide better outcomes and symptom improvement. We are conducting the RECOVER clinical study to further evaluate the benefits of VNS Therapy for Depression. Discover more

Drug-Resistant Epilepsy
Our VNS Therapy® System for drug-resistant epilepsy has treated more than 125,000 patients around the world. VNS Therapy can lead to fewer seizures, shorter seizures and better recovery after seizures. Discover more

Heart Failure
With Autonomic Regulation Therapy (ART) for heart failure, we strive to fix the heart by balancing the brain. ART uses a variant of VNS Therapy® called VITARIA®. It aims to correct an imbalance that causes the heart to not pump enough blood. Discover more

Obstructive Sleep Apnea
Our THN Sleep Therapy includes an implantable device called the aura6000. The CPAP-alternative uses electrical pulses to treat Obstructive Sleep Apnea. Discover more

Pro forma revenues by geography 1

  • Europe
  • United States
  • Rest of World

1) Rounded numbers based on full-year 2021 revenue.

Pro forma revenues by business 1

  • Cardiopulmonary
  • Neuromodulation
  • Advanced Circulatory Support

1) Rounded numbers based on full-year 2021 revenue.

Recommended

Featured News & Events

LivaNova Reports Second-Quarter 2022 Results

Aug 3, 2022
Read News

LivaNova to Announce Second-Quarter 2022 Results

Jun 22, 2022
Read News

LivaNova Elects Peter Wilver to Board of Directors

Jun 14, 2022
Read News

2Q 2022 LivaNova PLC Earnings Conference Call

Aug 3, 2022 at 8:00 AM EDT
See Event

1Q 2022 LivaNova PLC Earnings Conference Call

May 4, 2022 at 8:00 AM EDT
See Event

4Q and Full-Year 2021 LivaNova PLC Earnings Conference Call

Feb 23, 2022 at 8:00 AM EST
See Event